No revenue or guidance provided; the stock will trade on upcoming catalysts (CIRRUS-HCM data, GRAND CANYON results). Monitor for Phase 2 HCM data in Q2 2026 and cash runway - current $499.6M should fund operations into late 2026.
Price Chart
Executive Summary
Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenue biotech highlighted positive long-term sevasemten stabilization data and reiterated key catalysts (CIRRUS-HCM 12-week data in Q2 2026, GRAND CANYON pivotal results in Q4 2026). Cash decreased to $499.6M, with R&D spending up YoY as pipeline programs advanced.
Key Financial Metrics
Key Facts
- Net loss per share $0.46 vs consensus $0.48 beat (5.2% surprise)
- Cash, cash equivalents and marketable securities $499.6M as of March 31, 2026
- R&D expenses $42.7M (up from $36.8M in Q1 2025) due to increased EDG-7500 and EDG-15400 activity
- Net loss widened to $49.0M from $40.8M in Q1 2025
- Positive long-term sevasemten data showing functional stabilization up to 3.5 years in Becker MD
- CIRRUS-HCM Phase 2 12-week data expected Q2 2026; GRAND CANYON pivotal results Q4 2026
Financial Impact
No revenue; net loss increased ~20% YoY. Cash burn $30.5M during Q1 2026.
Risk Factors
- Clinical trial failures could impair stock significantly; GRAND CANYON and CIRRUS-HCM are binary events.
- Cash burn rate increasing; may require financing within 12-18 months.
- Pre-revenue biotech with no approved products - volatility expected.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-056783 |
| Document: tm2613489d1_8k.htm | 0001104659-26-056783 |
| Document: 0001104659-26-056783-index-headers.html | 0001104659-26-056783 |
| Document: 0001104659-26-056783-index.html | 0001104659-26-056783 |
| Document: 0001104659-26-056783.txt | 0001104659-26-056783 |
| 8-K Data (Synthetic) | 0001104659-26-056783 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 6, 2026 8w ago | 8-K | $44.42 $41.95 | ▼ −5.56% | ▼ −6.16% | $41.22 (−7.20%) |
Jul 13, 2026 11w ago | 8-K | $41.27 $44.58 | ▲ +8.02% | ▲ +4.84% | $41.22 (−0.12%) |
Jun 1, 2026 17w ago | 8-K | $40.26 $40.63 | ▲ +0.92% | ▲ +2.22% | $41.22 (+2.38%) |
May 7, 2026 21w ago | 8-K | $35.58 $36.21 | ▲ +1.77% | ▼ −1.37% | $41.22 (+15.85%) |
Apr 23, 2026 23w ago | DEFA14A | $31.58 $32.69 | ▲ +3.51% | ▼ −0.51% | $41.22 (+30.53%) |
Mar 27, 2026 26w ago | 144 | $30.28 $30.99 | ▲ +2.34% | ▼ −10.25% | $41.22 (+36.13%) |
Feb 26, 2026 31w ago | 8-K | $29.66 $31.65 | ▲ +6.71% | ▲ +13.11% | $41.22 (+38.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access